DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 4 filers reported holding DENALI THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,383,023 | -30.1% | 357,878 | 0.0% | 0.05% | -31.6% |
| Q2 2023 | $10,560,980 | +39.2% | 357,878 | 0.0% | 0.08% | +43.4% |
| Q1 2023 | $7,589,405 | -23.7% | 357,878 | 0.0% | 0.05% | -20.9% |
| Q4 2022 | $9,952,121 | -9.4% | 357,878 | 0.0% | 0.07% | -13.0% |
| Q3 2022 | $10,984,000 | +15.6% | 357,878 | +10.8% | 0.08% | -1.3% |
| Q2 2022 | $9,502,000 | +108.7% | 322,882 | +128.2% | 0.08% | +151.6% |
| Q1 2022 | $4,552,000 | -27.9% | 141,507 | 0.0% | 0.03% | -22.5% |
| Q4 2021 | $6,311,000 | +96.1% | 141,507 | +121.9% | 0.04% | +81.8% |
| Q3 2021 | $3,218,000 | -35.7% | 63,781 | 0.0% | 0.02% | -35.3% |
| Q2 2021 | $5,003,000 | – | 63,781 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
| ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
| Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
| Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
| Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
| Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
| Artal Group S.A. | 802,899 | $16,564 | 0.71% |